New scan could reveal if breast cancer drugs are working in days

NCT ID NCT02608216

Ongoing Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tests whether a special PET scan using a tracer called FLT can show how breast cancer tumors respond to a combination of two drugs, ribociclib and paclitaxel. The study involves 20 people with metastatic breast cancer that has spread beyond the liver and bone. Researchers will take scans before and during treatment to see if changes in tumor activity can predict whether the therapy is working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (LEE011) and paclitaxel
What this could lead to: If successful, this imaging method could help doctors quickly tell if a breast cancer treatment is working, potentially guiding more personalized therapy.
What could go wrong: This is a very small, early-phase study focused on imaging, not on proving the treatment works. The results may not apply to all patients or lead to a direct benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM METASTATIC BREAST CANCER RB+ BREAST CANCER

Contacts and locations

Locations

University of Pennsylvania Hospital

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.